ORM-3819

a phosphodiesterase III inhibitor with cardiotonic activity; structure in first source

Also Known As:

6-(4-(N'-(4-hydroxy-3-methoxy-2-nitrobenzylidene)hydrazino)phenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Myocardial Stunning (Stunned Myocardium) 03/15/2016 - "In an in vivo dog model of myocardial stunning, ORM-3819 restored the depressed LV+dP/dtmax and improved % segmental shortening (%SS) in the ischemic area (to 18.8±3), which was reduced after the ischaemia-reperfusion insult (from 24.1±2.1 to 11.0±2.4). "
2.	Coronary Vasospasm (Coronary Artery Vasospasm) 01/01/2019 - "These results suggest that ORM-3819 is a potent vasodilating agent able to relieve coronary artery vasospasm by causing hyperpolarization of vascular smooth muscle cells through processes involving activation of voltage-gated potassium channels."

1.	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)